ICON plc | Clinical Research Organisation (CRO) for Drug Development

The key to remarkable rare disease registries

Building trust and collaboration with patient advocacy organisations

Effective participation support strategy is critical to trial efficiency

Critical success factors for rare disease clinical trials

Spotlight on regulatory reforms in China

Although China’s regulatory reforms have attracted many foreign companies to conduct trials in China, there are still challenges.

Environmental, Social & Governance 2021

Translating intent to impact.

Featured Services

Seeking parallel consultation from regulators and HTA bodies in Europe

Market Access

Expertise in mission-critical pricing, market access, and reimbursement.

Site & Patient Solutions

Transforming recruitment through patient-centric trials and real-world, real-time data.

Biotech

ICON provides full service outsourcing and flexible support for biotech specific needs such as due diligence and asset valuation.

Functional Resourcing

From recruitment of a single clinical professional to managing entire global functions.

Increasing Site and Patient Compliance

FIRECREST: Digital solutions to increase efficiency in clinical trials by driving site performance.

ICON Insights

06 December 2022

Pharmacovigilance outsourcing: Tips for selecting a service provider

Selecting a vendor requires careful exploration and planning to ensure a successful relationship between sponsor and outsourcing partner.

05 December 2022

MDR certification bottleneck

It is of paramount importance that companies with expiring certification begin the process to remain compliant under the new MDR. Read more about identified challenges and solutions.

01 December 2022

Implementing surveillance measures to prioritise patient safety

Patient centricity is a top priority at ICON. We use the latest technologies to detect and manage potential risks posed by medicinal products in accordance with GVP.

30 November 2022

US marketing approval of drugs and devices by sole reliance on foreign (non-US) clinical data

Clinical research is becoming increasingly global. Sponsors may choose to conduct multinational clinical studies under a variety of scenarios at both foreign (non-US) sites and US sites.

29 November 2022

Challenges and key success factors for linguistic validation and COA translation within clinical trials

This blog outlines challenges and key success factors in the linguistic validation process.

23 November 2022

Chemistry, manufacturing, and controls in drug development and life cycle management

Chemistry, Manufacturing, and Controls (CMC) is the “first step” to ensuring drug quality throughout the product development lifecycle.

18 November 2022

Understanding the impact of the Clinical Trial Liaison (CTL) function

The impact of the clinical trial liaison function (CTL) in developing and delivering optimal clinical trials.

17 November 2022

Empowering children with education through clinical trials

In support of World Children’s Day 2022, this blog shares strategies to empower children every day through education, specifically in clinical trials.

17 November 2022

A rare partnership: collaborating with patient advocacy organisations for rare disease registries

Rare disease registries: practical ways to build trust and collaboration with patient advocacy groups.

Services

Sectors

Therapeutics

Innovation

Insights

News & Events

About ICON

Healthcare Intelligence

Sponsor and CRO pharmacovigilance and safety alliances

Beyond buzzwords: Diversity, equity and inclusion in rare disease clinical trials

Transfer of marketing authorisation